HRP20150639T1 - Postupak za proäśišä†avanje proteina - Google Patents
Postupak za proäśišä†avanje proteina Download PDFInfo
- Publication number
- HRP20150639T1 HRP20150639T1 HRP20150639TT HRP20150639T HRP20150639T1 HR P20150639 T1 HRP20150639 T1 HR P20150639T1 HR P20150639T T HRP20150639T T HR P20150639TT HR P20150639 T HRP20150639 T HR P20150639T HR P20150639 T1 HRP20150639 T1 HR P20150639T1
- Authority
- HR
- Croatia
- Prior art keywords
- host cell
- recombinant
- recombinant protein
- seq
- extract
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 27
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 13
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 13
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 claims 6
- 108020003519 protein disulfide isomerase Proteins 0.000 claims 6
- 230000001580 bacterial effect Effects 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 2
- 108010016626 Dipeptides Proteins 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 238000004587 chromatography analysis Methods 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 1
- 229960000583 acetic acid Drugs 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000011536 extraction buffer Substances 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 239000012362 glacial acetic acid Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 102000057041 human TNF Human genes 0.000 claims 1
- 238000004255 ion exchange chromatography Methods 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Claims (25)
1. Postupak za pročišćavanje rekombinantnog proteina iz gram-negativnog bakterijskog uzorka stanice domaćina ili njezinog ekstrakta pri čemu navedena stanica domaćina izražava rekombinantni protein i rekombinantnu disulfid izomerazu DsbC; pri čemu postupaka sadrži:
a) podešavanje pH uzorka stanice domaćina, ili njezinog ekstrakta do pH 5 ili manje da se istaloži rekombinantna disulfid izomeraza; i
b) odvajanje istaložene rekombinantne disulfid izomeraze iz rekombinantnog proteina da se proizvede uzorak rekombinantnog proteina.
2. Postupak prema patentnom zahtjevu 1, pri čemu je pH uzorka stanice domaćina ili njezinog ekstrakta podešen na pH od 4.5 ili manje.
3. Postupak prema patentnom zahtjevu 2, pri čemu je pH uzorka stanice domaćina ili njezinog ekstrakta podešen na pH od 4.5 do 3.0.
4. Postupak prema patentnom zahtjevu 2, pri čemu je pH uzorka stanice domaćina ili njezinog ekstrakta podešen na pH od 3 ili manje.
5. Postupak prema patentnom zahtjevu 4, pri čemu je u koraku a) dipeptid stanice domaćina vezujućeg proteina dalje istaložen i u koraku b) dipeptid stanice domaćina je dalje odvojen od rekombinantnog proteina.
6. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu disulfid izomeraza sadrži dodatak histidina.
7. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu je gram-negativna bakterijska stanica domaćina E. coli.
8. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu stanica domaćina sadrži Fkpa i/ili Skp.
9. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu u koraku a) pH uzorka stanice domaćina ili njezinog ekstrakta je podešen na pH od manje od 5 upotrebom ledene octene kiseline.
10. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu uzorak stanice domaćina ili njezinog ekstrakta se drži na pH od 5 ili manje tokom jednog sata ili manje.
11. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu separacija u koraku b) sadrži centrifugiranje i/ili filtriranje.
12. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu nakon koraka b) postupak sadrži dalji korak pročišćavanja uzorka rekombinantnog proteina kromatografijom.
13. Postupak prema patentnom zahtjevu 11, pri čemu je kromatografija kromatografija ionske izmjene.
14. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu nakon koraka b) pH uzorka rekombinantnog proteina je podešena na pH od 5 do 7.
15. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu pre koraka a) pufer za ekstrakciju je dodat uzorku stanice domaćina ili njegovom ekstraktu i uzorak stanice domaćina ili njegov ekstrakt je podvrgnut koraku termičke obrade.
16. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu rekombinantni protein ima pl od 6 do 9.
17. Postupak prema patentnom zahtjevu 16, pri čemu rekombinantni protein ima pl od 8 do 9.
18. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu rekombinantni protein je rekombinantno antitijelo.
19. Postupak prema patentnom zahtjevu 18, pri čemu je rekombinantno antitijelo monoklonalno, humanizirano ili himerno antitijelo, ili njihov fragment, kao što je njihov vezujući fragment.
20. Postupak prema patentnom zahtjevu 18 ili zahtjevu 19, pri čemu je rekombinantno antitijelo Fab ili Fab fragment.
21. Postupak prema bilo kojem od patentnih zahtjeva 18 do 20, pri čemu je rekombinantno antitijelo specifično za humani TNFɑ.
22. Postupak prema patentnom zahtjevu 21, pri čemu antitijelo sadrži teški lanac gdje varijabilna domena sadrži CDR koji ima sekvencu danu u SEQ ID NO:1 za CDRH1, SEQ ID NO:2, za CDRH2 i SEQ ID NO:3 za CDRH3 i laki lanac pri čemu varijabilna domena sadrži CDR koji ima sekvencu danu u SEQ ID NO:4 za CDRL1, SEQ ID NO:5 za CDRL2 i SEQ ID NO:6 za CDRL3.
23. Postupak prema patentnom zahtjevu 22, pri čemu antitijelo sadrži sekvencu varijabilne regije lakog lanca danu u SEQ ID NO: 7 i varijabilna regija teškog lanca je dana u SEQ ID NO: 8.
24. Postupak prema patentnom zahtjevu 23, pri čemu je antitijelo Fab fragment i sadrži teški lanac koji ima sekvencu danu u SEQ ID NO: 10 i laki lanac koji ima sekvencu danu u SEQ ID NO: 9.
25. Upotreba koraka podešavanja pH gram-negativnog bakterijskog uzorka stanice domaćina ili njezinog ekstrakta transformiranog ekspresijskim vektorom koji kodira rekombinantni protein na pH 5 ili manje kako bi se istaložila rekombinantna disulfid izomeraza stanice domaćina, odvojila istaložena rekombinantna disulfid izomeraza stanice domaćina iz rekombinantnog proteina i proizveo pročišćeni uzorak rekombinantnog proteina.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1012599.5A GB201012599D0 (en) | 2010-07-27 | 2010-07-27 | Process for purifying proteins |
| PCT/GB2011/001129 WO2012013930A2 (en) | 2010-07-27 | 2011-07-27 | Process for purifying proteins |
| EP11745810.9A EP2598516B8 (en) | 2010-07-27 | 2011-07-27 | Process for purifying proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150639T1 true HRP20150639T1 (hr) | 2015-07-17 |
Family
ID=42752868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150639TT HRP20150639T1 (hr) | 2010-07-27 | 2015-06-15 | Postupak za proäśišä†avanje proteina |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9751930B2 (hr) |
| EP (1) | EP2598516B8 (hr) |
| JP (1) | JP5935222B2 (hr) |
| KR (1) | KR101944121B1 (hr) |
| CN (1) | CN103189385B (hr) |
| AU (1) | AU2011284548B2 (hr) |
| BR (1) | BR112013000177B1 (hr) |
| CA (1) | CA2804099C (hr) |
| CY (1) | CY1116526T1 (hr) |
| DK (1) | DK2598516T3 (hr) |
| ES (1) | ES2537877T3 (hr) |
| GB (1) | GB201012599D0 (hr) |
| HR (1) | HRP20150639T1 (hr) |
| HU (1) | HUE026049T2 (hr) |
| IL (1) | IL224044A (hr) |
| ME (1) | ME02162B (hr) |
| MX (1) | MX337184B (hr) |
| PL (1) | PL2598516T3 (hr) |
| PT (1) | PT2598516E (hr) |
| RS (1) | RS54085B1 (hr) |
| SG (2) | SG186974A1 (hr) |
| SI (1) | SI2598516T1 (hr) |
| SM (1) | SMT201500142B (hr) |
| WO (1) | WO2012013930A2 (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2993231B1 (en) | 2009-09-24 | 2018-08-01 | UCB Biopharma SPRL | Bacterial strain for recombinant protein expression, having protease deficient degp retaining chaperone activity, and knocked out tsp and ptr genes |
| GB201000590D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
| GB201000591D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
| GB201000587D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
| GB201001791D0 (en) | 2010-02-03 | 2010-03-24 | Ucb Pharma Sa | Process for obtaining antibodies |
| HUE035674T2 (en) | 2011-07-13 | 2018-05-28 | Ucb Biopharma Sprl | Bacterial host strains expressing recombinant DSBC |
| GB201208367D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Biological product |
| KR102065355B1 (ko) * | 2012-05-31 | 2020-01-13 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 단백질 제조물 내의 응집체 양 감소를 위한 혼합 다관능 표면들의 사용 방법 |
| EP2855504B1 (en) * | 2012-05-31 | 2018-10-24 | Agency For Science, Technology And Research | Chromatographic purification of immunoglobulin g preparations with particles having multimodal functionalities |
| JP6875276B2 (ja) * | 2014-11-05 | 2021-05-19 | ジェネンテック， インコーポレイテッド | 細菌における２鎖タンパク質の生成方法 |
| EA201791424A1 (ru) | 2014-12-22 | 2017-10-31 | Юсб Биофарма Спрл | Получение белка |
| EA039002B1 (ru) | 2014-12-22 | 2021-11-19 | Юсб Биофарма Спрл | Способ получения белка |
| SG10202005917SA (en) * | 2015-03-06 | 2020-07-29 | Genentech Inc | Ultrapurified dsba and dsbc and methods of making and using the same |
| CN110272491B (zh) * | 2018-03-13 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | 一种抗pd-1抗体的纯化工艺 |
| JP7259131B2 (ja) * | 2019-08-05 | 2023-04-17 | ワッカー ケミー アクチエンゲゼルシャフト | 発酵法で組換えタンパク質を放出する細菌株 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| US5030570A (en) | 1988-06-30 | 1991-07-09 | The Eunice Kennedy Shriver Center For Mental Retardation | DNA encoding and method of expressing human monoamine oxidase type A |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
| US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| GB9215540D0 (en) | 1992-07-22 | 1992-09-02 | Celltech Ltd | Protein expression system |
| WO1997038123A1 (en) * | 1996-04-05 | 1997-10-16 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US6083715A (en) * | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
| DE60031533D1 (de) | 1999-06-29 | 2006-12-07 | Siga Technologies Inc | Test für degp-protease inhibitoren |
| GB0006398D0 (en) | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
| GB0013810D0 (en) * | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
| AU8867501A (en) | 2000-09-01 | 2002-03-13 | Biogen Inc | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| WO2002018446A2 (en) | 2000-09-01 | 2002-03-07 | Biogen, Inc. | Methods of designing and producing compounds having improved binding affinity for cd154 or other trimeric proteins |
| US7041479B2 (en) * | 2000-09-06 | 2006-05-09 | The Board Of Trustess Of The Leland Stanford Junior University | Enhanced in vitro synthesis of active proteins containing disulfide bonds |
| CZ304484B6 (cs) | 2000-12-14 | 2014-05-21 | Genentech, Inc. | Bakteriální hostitelské kmeny a způsob tvorby polypeptidu |
| JP4309656B2 (ja) | 2000-12-14 | 2009-08-05 | ジェネンテック・インコーポレーテッド | 原核生物で生成させた抗体とその用途 |
| TWI327597B (en) | 2001-08-01 | 2010-07-21 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
| WO2003018771A2 (en) | 2001-08-27 | 2003-03-06 | Genentech, Inc. | A system for antibody expression and assembly |
| GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
| NZ533056A (en) | 2001-11-16 | 2007-12-21 | Biogen Idec Inc | Polycistronic expression of antibodies |
| GB0129105D0 (en) | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
| EP2135879A3 (en) | 2002-06-28 | 2010-06-23 | Domantis Limited | Ligand |
| MXPA05004677A (es) * | 2002-10-31 | 2005-11-17 | Genentech Inc | Metodos y composiciones para aumentar la produccion de anticuerpos. |
| ATE528648T1 (de) | 2002-12-03 | 2011-10-15 | Ucb Pharma Sa | Verfahren zum nachweis antikörper-herstellender zellen |
| AU2004230670B2 (en) | 2003-01-09 | 2010-11-25 | Genentech, Inc. | Purification of polypeptides |
| GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| EP1639014B1 (en) | 2003-06-13 | 2010-09-22 | Biogen Idec MA Inc. | Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof |
| DE602004017726D1 (de) | 2003-06-30 | 2008-12-24 | Domantis Ltd | Pegylierte Single-domain-antikörper (dAb) |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| NZ580688A (en) | 2003-07-26 | 2012-03-30 | Biogen Idec Inc | Method of designing altered antibodies having improved antigen-binding affinity |
| CZ200755A3 (cs) | 2004-07-26 | 2007-04-11 | Biogen Idec Ma Inc. | Peptidy protilátek anti-CD154 |
| MX2007002856A (es) | 2004-09-02 | 2007-09-25 | Genentech Inc | Metodos para el uso de ligandos receptores de muerte y anticuerpos c20. |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| GB0425534D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Process for obtaining antibodies |
| ES2713859T3 (es) | 2007-03-22 | 2019-05-24 | Biogen Ma Inc | Proteínas de unión, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen específicamente a CD154 y usos de los mismos |
| US7662587B1 (en) | 2009-03-05 | 2010-02-16 | E. I. Du Pont De Nemours And Company | Gene knockout mutations that increase peptide production |
| EP2993231B1 (en) | 2009-09-24 | 2018-08-01 | UCB Biopharma SPRL | Bacterial strain for recombinant protein expression, having protease deficient degp retaining chaperone activity, and knocked out tsp and ptr genes |
| US8470552B2 (en) | 2009-10-12 | 2013-06-25 | Keck Graduate Institute | Strategy to reduce lactic acid production and control PH in animal cell culture |
| EP2496601B1 (en) | 2009-11-05 | 2017-06-07 | F. Hoffmann-La Roche AG | Methods and composition for secretion of heterologous polypeptides |
| GB201000591D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
| GB201000590D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
| GB201000588D0 (en) * | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
| GB201000587D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
| GB201001791D0 (en) | 2010-02-03 | 2010-03-24 | Ucb Pharma Sa | Process for obtaining antibodies |
| HUE035674T2 (en) | 2011-07-13 | 2018-05-28 | Ucb Biopharma Sprl | Bacterial host strains expressing recombinant DSBC |
| EP2546267A1 (en) | 2011-07-13 | 2013-01-16 | UCB Pharma S.A. | Bacterial host strain expressing recombinant DsbC |
| GB201208367D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Biological product |
-
2010
- 2010-07-27 GB GBGB1012599.5A patent/GB201012599D0/en not_active Ceased
-
2011
- 2011-07-27 CN CN201180036417.8A patent/CN103189385B/zh active Active
- 2011-07-27 PL PL11745810T patent/PL2598516T3/pl unknown
- 2011-07-27 BR BR112013000177-1A patent/BR112013000177B1/pt not_active IP Right Cessation
- 2011-07-27 MX MX2013000899A patent/MX337184B/es active IP Right Grant
- 2011-07-27 ME MEP-2015-94A patent/ME02162B/me unknown
- 2011-07-27 PT PT117458109T patent/PT2598516E/pt unknown
- 2011-07-27 SG SG2013001318A patent/SG186974A1/en unknown
- 2011-07-27 HU HUE11745810A patent/HUE026049T2/en unknown
- 2011-07-27 SI SI201130516T patent/SI2598516T1/sl unknown
- 2011-07-27 DK DK11745810.9T patent/DK2598516T3/da active
- 2011-07-27 RS RS20150429A patent/RS54085B1/en unknown
- 2011-07-27 US US13/812,350 patent/US9751930B2/en active Active
- 2011-07-27 JP JP2013521208A patent/JP5935222B2/ja active Active
- 2011-07-27 ES ES11745810.9T patent/ES2537877T3/es active Active
- 2011-07-27 AU AU2011284548A patent/AU2011284548B2/en active Active
- 2011-07-27 KR KR1020137004911A patent/KR101944121B1/ko active IP Right Grant
- 2011-07-27 EP EP11745810.9A patent/EP2598516B8/en active Active
- 2011-07-27 SG SG2014005441A patent/SG196862A1/en unknown
- 2011-07-27 CA CA2804099A patent/CA2804099C/en active Active
- 2011-07-27 WO PCT/GB2011/001129 patent/WO2012013930A2/en active Application Filing
-
2012
- 2012-12-31 IL IL224044A patent/IL224044A/en active IP Right Grant
-
2015
- 2015-06-15 HR HRP20150639TT patent/HRP20150639T1/hr unknown
- 2015-06-18 SM SM201500142T patent/SMT201500142B/xx unknown
- 2015-06-23 CY CY20151100535T patent/CY1116526T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150639T1 (hr) | Postupak za proäśišä†avanje proteina | |
| HRP20180226T1 (hr) | Bakterijski soj domaćina koji eksprimira rekombinantnu dsbc | |
| JP2018521638A5 (hr) | ||
| US10149903B2 (en) | Fully human antibody against respiratory syncytical virus | |
| HRP20190897T1 (hr) | Laki lanac humaniziranih miševa | |
| HRP20200464T1 (hr) | Metoda modifikacije polipeptida za pročišćavanje polipeptidnih multimera | |
| HRP20191608T1 (hr) | Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida | |
| HRP20180516T1 (hr) | Humanizirana protutijela specifična za protofibrilni oblik amiloidnog-beta peptida | |
| JP2018085988A5 (hr) | ||
| CN113912710B (zh) | 抗新型冠状病毒n蛋白的单克隆抗体及其应用 | |
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| RU2017125758A (ru) | Антитела к с5 и способы их применения | |
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| RU2015150149A (ru) | Составы на основе биспецифических антител к il-4/il-13 | |
| RU2014146503A (ru) | Белки, связывающие антиген - лиганд cd30 человека | |
| AR068566A1 (es) | Proteinas fijadoras de antigeno de factor de crecimiento del tipo factor de crecimiento epidermico fijador de heparina | |
| NZ603972A (en) | Anti-fgfr2 antibodies | |
| HRP20130877T1 (hr) | Antitijela koja neutraliziraju humani citomegalovirus i njihova primjena | |
| NZ623347A (en) | Novel anti-dr5 antibody | |
| JP2019038834A (ja) | 分泌様免疫グロブリンを含む組成物 | |
| JP2011528902A5 (hr) | ||
| NZ598202A (en) | High affinity human antibodies to human angiopoietin-2 | |
| RU2588467C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| PE20141660A1 (es) | PROTEINAS DE UNION A ANTIGENO DE TNF-ALFA CON UNION A FcRn INCREMENTADA | |
| BR112014015101A8 (pt) | métodos para intensificar eficiência de etapas de cromatografia a jusante para purificação de anticorpos |